Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Rolien Bosch"'
1
Akademický článek
Quantification of the effect of GLP‐1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model
Autor: Rolien Bosch, Eric J. G. Sijbrands, Nelleke Snelder
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 9, Pp 1488-1502 (2024)
Abstract Obesity has become a major public health concern worldwide. Pharmacological interventions with the glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have shown promising results in facilitating weight loss and improving metabolic ou
Externí odkaz: https://doaj.org/article/c309e862c59f4962bd343f92b13eebff
Zobrazit plný text záznamu
2
Akademický článek
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development
Autor: Martijn vanNoort, Martijn Ruppert, Joost DeJongh, Eleonora Marostica, Rolien Bosch, Emir Mešić, Nelleke Snelder
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 7, Pp 1170-1179 (2024)
Abstract In pharmacometric modeling, it is often important to know whether the data is sufficiently rich to identify the parameters of a proposed model. While it may be possible to assess this based on the results of a model fit, it is often difficul
Externí odkaz: https://doaj.org/article/e80746c66672430b9aa2571b5c7e641f
Zobrazit plný text záznamu
3
Akademický článek
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist
Autor: Rolien Bosch, Marcella Petrone, Rosalin Arends, Paolo Vicini, Eric J. G. Sijbrands, Sven Hoefman, Nelleke Snelder
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 3, Pp 302-317 (2022)
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) and dual GLP‐1/glucagon receptor agonists improve glycaemic control and cause significant weight loss in patients with type 2 diabetes.1 These effects are driven in part
Externí odkaz: https://doaj.org/article/ad6f701a56624bc9a8d881a64c27d94f
Zobrazit plný text záznamu
4
Akademický článek
Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment
Autor: Chi‐Chung Li, Tiffini Voss, Ken Kowalski, Bei Yang, Huub Jan Kleijn, Christopher J. Jones, Rolien Bosch, David Michelson, Matthew DeAngelis, Yang Xu, Iris Xie, Prajakti A. Kothare
Publikováno v: Clinical and Translational Science, Vol 13, Iss 3, Pp 482-490 (2020)
Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) m
Externí odkaz: https://doaj.org/article/eb872eb56df648a2b8a35bd1a4180f5a
Zobrazit plný text záznamu
5
Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment
Autor: Bei Yang, Prajakti A. Kothare, Tiffini Voss, Iris Xie, Chi-Chung Li, Yang Xu, Matthew DeAngelis, David Michelson, Ken Kowalski, Christopher Jones, Rolien Bosch, Huub Jan Kleijn
Publikováno v: Clinical and Translational Science, Vol 13, Iss 3, Pp 482-490 (2020)
Clinical and Translational Science
Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99423d5b7c0b41783b3e3eef16d90ef9
https://doaj.org/article/eb872eb56df648a2b8a35bd1a4180f5a
Zobrazit plný text záznamu
6
A PK-PD model-based assessment of sugammadex effects on coagulation parameters
Autor: Annelieke C. Kruithof, Sandra A.G. Visser, Huub-Jan Kleijn, Jacobus Burggraaf, Pieter-Jan de Kam, Amy O. Johnson-Levonas, Marie-José van Lierop, Rik de Greef, Rolien Bosch
Publikováno v: European Journal of Pharmaceutical Sciences. 84:9-17
Exposure-response analyses of sugammadex on activated partial thromboplastin time (APTT) and prothrombin time international normalized ratio (PT(INR)) were performed using data from two clinical trials in which subjects were co-treated with anti-coag
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c97d56b7a7c90cf1a63e03f70f851f1
https://doi.org/10.1016/j.ejps.2015.12.028
Zobrazit plný text záznamu
7
Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling
Autor: Eugene E. Marcantonio, Ken Kowalski, Prajakti A. Kothare, Tiffini Voss, Iris Xie, Marissa F. Dockendorf, Huub Jan Kleijn, Kevin P. Bateman, Chi-Chung Li, Christopher Jones, Rolien Bosch, Bob Thornton, Bei Yang, Yang Xu
Publikováno v: Journal of clinical pharmacology. 58(3)
Merck & Co., Inc. (Kenilworth, New Jersey) has recently published an integrated strategy for implementation of dried blood spots (DBS) in late-stage trials for population pharmacokinetic (PK) modeling. We applied this strategy for another late-stage
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee95d8b09834b762c0b3ca3ac1014df3
https://pubmed.ncbi.nlm.nih.gov/29136283
Zobrazit plný text záznamu
8
X-ray Structures of Progesterone Receptor Ligand Binding Domain in Its Agonist State Reveal Differing Mechanisms for Mixed Profiles of 11β-Substituted Steroids
Autor: Marcel van Duin, Rita Azevedo, Hans Hamersma, Diep Vu-Pham, Arthur Oubrie, Scott J. Lusher, Rolien Bosch, Bert Kazemier, Hans C.A. Raaijmakers, Jacob de Vlieg, Koen J. Dechering, Ross McGuire
Publikováno v: Journal of Biological Chemistry, 287, 20333-20343
Journal of Biological Chemistry, 287, 24, pp. 20333-20343
Contains fulltext : 103894.pdf (Publisher’s version ) (Open Access) We present here the x-ray structures of the progesterone receptor (PR) in complex with two mixed profile PR modulators whose functional activity results from two differing molecula
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5603237fee702c88c44068b45f204787
https://doi.org/10.1074/jbc.m111.308403
Zobrazit plný text záznamu
9
Structural Basis for Agonism and Antagonism for a Set of Chemically Related Progesterone Receptor Modulators
Autor: Ross McGuire, Rolien Bosch, Jacob de Vlieg, Niall M. Hamilton, Olaf Nimz, Koen J. Dechering, Angus R. Brown, Scott J. Lusher, Tsang Wai Lam, Arthur Oubrie, Diep Vu-Pham, Hans C.A. Raaijmakers
Publikováno v: Journal of Biological Chemistry, 286, 35079-35086
Journal of Biological Chemistry, 286, 40, pp. 35079-35086
The progesterone receptor is able to bind to a large number and variety of ligands that elicit a broad range of transcriptional responses ranging from full agonism to full antagonism and numerous mixed profiles inbetween. We describe here two new pro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe67a191b82ca4f7414febeccbc79a8
https://doi.org/10.1074/jbc.m111.273029
Zobrazit plný text záznamu
10
Akademický článek
Quantification of the effect of GLP‐1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model.
Autor: Bosch, Rolien1,2 (AUTHOR) r.bosch@erasmusmc.nl, Sijbrands, Eric J. G.2 (AUTHOR), Snelder, Nelleke1 (AUTHOR)
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. Sep2024, Vol. 13 Issue 9, p1488-1502. 15p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje